Retinal and choroidal microangiopathies: Therapeutic opportunities

A. Afzal, L. C. Shaw, A. V. Ljubimov, M. E. Boulton, M. S. Segal, M. B. Grant

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Pathological angiogenesis in the retina and underlying choroid is a major cause of visual impairment in all age groups. The last decade has seen an explosion in the clinical availability of antiangiogenic compounds. Emphasis has been placed on inhibitors of the VEGF signaling pathway and considerable success has been achieved with aptamers and antibodies that bind VEGF. However, regression of neovascularization is rarely permanent and the regrowth of new vessels, often within a few months, requires multiple applications of drug. A number of antiangiogenic factors such as IGFBP3, SDF-1 blockers, PEDF, γ-secretase, Delta-like ligand 4, and integrin antagonists have been identified, which act either indirectly on the VEGF system or independent of it. The importance of other candidates such as HIF-1α and protein kinase CK2, which act as "master" regulators of angiogenesis, offer realistic alternative targets for pharmacological intervention. The concept of combination therapy is rapidly gaining interest in the eye field and co-administration of two angiogenic agents (e.g., a CK2 inhibitor with a somatostatin analog, octreotide) are often significantly more effective at inhibiting retinal angiogenesis than either drug alone. The following review will discuss the current therapies available for aberrant ocular angiogenesis, consider new candidate targets for development of antiangiogenic compounds and emphasize the importance of combinatorial pharmacological agents in the treatment of such a dynamic cellular event as angiogenesis.

Original languageEnglish (US)
Pages (from-to)131-144
Number of pages14
JournalMicrovascular Research
Volume74
Issue number2-3
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Pathologic Neovascularization
Pharmacology
Casein Kinase II
Amyloid Precursor Protein Secretases
Octreotide
Choroid
Explosions
Vision Disorders
Somatostatin
Integrins
Pharmaceutical Preparations
Retina
Therapeutics
Age Groups
Availability
Antibodies
delta protein

Keywords

  • γ-secretase
  • Age-related macular degeneration
  • Angiogenesis
  • Antiangiogenic
  • CD133
  • CD14
  • CD34
  • Choroidal neovascularization
  • CXCR4
  • Delta-like ligand 4
  • Endothelial progenitor cell
  • Hematopoietic stem cell
  • Hypoxia
  • IGF-1
  • IGF-1R
  • IGFBP-3
  • Ischemia
  • PEDF
  • Proliferative retinopathy
  • Protein kinase CK2
  • Retinopathy of prematurity
  • SDF-1
  • Somatostatin analogs
  • Therapies
  • Vascularization
  • VEGF
  • VEGFR-1
  • VEGFR-2

ASJC Scopus subject areas

  • Biochemistry
  • Cardiology and Cardiovascular Medicine

Cite this

Afzal, A., Shaw, L. C., Ljubimov, A. V., Boulton, M. E., Segal, M. S., & Grant, M. B. (2007). Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvascular Research, 74(2-3), 131-144. https://doi.org/10.1016/j.mvr.2007.04.011

Retinal and choroidal microangiopathies : Therapeutic opportunities. / Afzal, A.; Shaw, L. C.; Ljubimov, A. V.; Boulton, M. E.; Segal, M. S.; Grant, M. B.

In: Microvascular Research, Vol. 74, No. 2-3, 09.2007, p. 131-144.

Research output: Contribution to journalArticle

Afzal, A, Shaw, LC, Ljubimov, AV, Boulton, ME, Segal, MS & Grant, MB 2007, 'Retinal and choroidal microangiopathies: Therapeutic opportunities', Microvascular Research, vol. 74, no. 2-3, pp. 131-144. https://doi.org/10.1016/j.mvr.2007.04.011
Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvascular Research. 2007 Sep;74(2-3):131-144. https://doi.org/10.1016/j.mvr.2007.04.011
Afzal, A. ; Shaw, L. C. ; Ljubimov, A. V. ; Boulton, M. E. ; Segal, M. S. ; Grant, M. B. / Retinal and choroidal microangiopathies : Therapeutic opportunities. In: Microvascular Research. 2007 ; Vol. 74, No. 2-3. pp. 131-144.
@article{104cdca3e37f46e7b5702c6b2577d4dd,
title = "Retinal and choroidal microangiopathies: Therapeutic opportunities",
abstract = "Pathological angiogenesis in the retina and underlying choroid is a major cause of visual impairment in all age groups. The last decade has seen an explosion in the clinical availability of antiangiogenic compounds. Emphasis has been placed on inhibitors of the VEGF signaling pathway and considerable success has been achieved with aptamers and antibodies that bind VEGF. However, regression of neovascularization is rarely permanent and the regrowth of new vessels, often within a few months, requires multiple applications of drug. A number of antiangiogenic factors such as IGFBP3, SDF-1 blockers, PEDF, γ-secretase, Delta-like ligand 4, and integrin antagonists have been identified, which act either indirectly on the VEGF system or independent of it. The importance of other candidates such as HIF-1α and protein kinase CK2, which act as {"}master{"} regulators of angiogenesis, offer realistic alternative targets for pharmacological intervention. The concept of combination therapy is rapidly gaining interest in the eye field and co-administration of two angiogenic agents (e.g., a CK2 inhibitor with a somatostatin analog, octreotide) are often significantly more effective at inhibiting retinal angiogenesis than either drug alone. The following review will discuss the current therapies available for aberrant ocular angiogenesis, consider new candidate targets for development of antiangiogenic compounds and emphasize the importance of combinatorial pharmacological agents in the treatment of such a dynamic cellular event as angiogenesis.",
keywords = "γ-secretase, Age-related macular degeneration, Angiogenesis, Antiangiogenic, CD133, CD14, CD34, Choroidal neovascularization, CXCR4, Delta-like ligand 4, Endothelial progenitor cell, Hematopoietic stem cell, Hypoxia, IGF-1, IGF-1R, IGFBP-3, Ischemia, PEDF, Proliferative retinopathy, Protein kinase CK2, Retinopathy of prematurity, SDF-1, Somatostatin analogs, Therapies, Vascularization, VEGF, VEGFR-1, VEGFR-2",
author = "A. Afzal and Shaw, {L. C.} and Ljubimov, {A. V.} and Boulton, {M. E.} and Segal, {M. S.} and Grant, {M. B.}",
year = "2007",
month = "9",
doi = "10.1016/j.mvr.2007.04.011",
language = "English (US)",
volume = "74",
pages = "131--144",
journal = "Microvascular Research",
issn = "0026-2862",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - Retinal and choroidal microangiopathies

T2 - Therapeutic opportunities

AU - Afzal, A.

AU - Shaw, L. C.

AU - Ljubimov, A. V.

AU - Boulton, M. E.

AU - Segal, M. S.

AU - Grant, M. B.

PY - 2007/9

Y1 - 2007/9

N2 - Pathological angiogenesis in the retina and underlying choroid is a major cause of visual impairment in all age groups. The last decade has seen an explosion in the clinical availability of antiangiogenic compounds. Emphasis has been placed on inhibitors of the VEGF signaling pathway and considerable success has been achieved with aptamers and antibodies that bind VEGF. However, regression of neovascularization is rarely permanent and the regrowth of new vessels, often within a few months, requires multiple applications of drug. A number of antiangiogenic factors such as IGFBP3, SDF-1 blockers, PEDF, γ-secretase, Delta-like ligand 4, and integrin antagonists have been identified, which act either indirectly on the VEGF system or independent of it. The importance of other candidates such as HIF-1α and protein kinase CK2, which act as "master" regulators of angiogenesis, offer realistic alternative targets for pharmacological intervention. The concept of combination therapy is rapidly gaining interest in the eye field and co-administration of two angiogenic agents (e.g., a CK2 inhibitor with a somatostatin analog, octreotide) are often significantly more effective at inhibiting retinal angiogenesis than either drug alone. The following review will discuss the current therapies available for aberrant ocular angiogenesis, consider new candidate targets for development of antiangiogenic compounds and emphasize the importance of combinatorial pharmacological agents in the treatment of such a dynamic cellular event as angiogenesis.

AB - Pathological angiogenesis in the retina and underlying choroid is a major cause of visual impairment in all age groups. The last decade has seen an explosion in the clinical availability of antiangiogenic compounds. Emphasis has been placed on inhibitors of the VEGF signaling pathway and considerable success has been achieved with aptamers and antibodies that bind VEGF. However, regression of neovascularization is rarely permanent and the regrowth of new vessels, often within a few months, requires multiple applications of drug. A number of antiangiogenic factors such as IGFBP3, SDF-1 blockers, PEDF, γ-secretase, Delta-like ligand 4, and integrin antagonists have been identified, which act either indirectly on the VEGF system or independent of it. The importance of other candidates such as HIF-1α and protein kinase CK2, which act as "master" regulators of angiogenesis, offer realistic alternative targets for pharmacological intervention. The concept of combination therapy is rapidly gaining interest in the eye field and co-administration of two angiogenic agents (e.g., a CK2 inhibitor with a somatostatin analog, octreotide) are often significantly more effective at inhibiting retinal angiogenesis than either drug alone. The following review will discuss the current therapies available for aberrant ocular angiogenesis, consider new candidate targets for development of antiangiogenic compounds and emphasize the importance of combinatorial pharmacological agents in the treatment of such a dynamic cellular event as angiogenesis.

KW - γ-secretase

KW - Age-related macular degeneration

KW - Angiogenesis

KW - Antiangiogenic

KW - CD133

KW - CD14

KW - CD34

KW - Choroidal neovascularization

KW - CXCR4

KW - Delta-like ligand 4

KW - Endothelial progenitor cell

KW - Hematopoietic stem cell

KW - Hypoxia

KW - IGF-1

KW - IGF-1R

KW - IGFBP-3

KW - Ischemia

KW - PEDF

KW - Proliferative retinopathy

KW - Protein kinase CK2

KW - Retinopathy of prematurity

KW - SDF-1

KW - Somatostatin analogs

KW - Therapies

KW - Vascularization

KW - VEGF

KW - VEGFR-1

KW - VEGFR-2

UR - http://www.scopus.com/inward/record.url?scp=35748946948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748946948&partnerID=8YFLogxK

U2 - 10.1016/j.mvr.2007.04.011

DO - 10.1016/j.mvr.2007.04.011

M3 - Article

C2 - 17585951

AN - SCOPUS:35748946948

VL - 74

SP - 131

EP - 144

JO - Microvascular Research

JF - Microvascular Research

SN - 0026-2862

IS - 2-3

ER -